Lung Cancer | Optimizing Biomarker-Based Decision-Making for Patients with Non-Small Cell Lung Cancer with EGFR Mutations or with Other Oncogene-Addicted Lung Cancers — Session 2

Featuring perspectives from Drs Marc Ladanyi, Andrew McKenzie and Helena Yu, including the following topics: Introduction: Role of Genomic Profiling in Non-Small Cell Lung Cancer (NSCLC) (0:00) Case: A woman in her mid-40s with newly diagnosed Stage IIB adenocarcinoma of the lung and an EGFR L858R mutation — Helena Yu, MD (13:33) Case: A man in his late 70s with metastatic NSCLC and osimertinib resistance due to acquired RET fusion — Marc Ladanyi, MD (23:08) Case: A woman in her mid-60s with newly diagnosed adenocarcinoma of the lung and an EGFR exon 20 mutation — Dr Yu (27:28) Case: A man in his late 70s with Stage IV adenocarcinoma of the lung and a RET fusion — Andrew J McKenzie, PhD (36:49) Case: A man in his late 60s with metastatic mucinous adenocarcinoma of the lung and a HER2 mutation — Spencer Bachow, MD (46:01) Case: A woman in her mid-30s with newly diagnosed metastatic NSCLC and an ALK mutation — Nikesh Jasani, MD (51:57) Case: A man in his late 70s with NSCLC and a TRK fusion — Dr McKenzie (53:24) Case: A woman in her mid-60s with discordant BRAF mutation testing results — Syed Zafar, MD (55:41) CME information and select publications